OBR Daily Commentary

forumImage

Incyte Shares Jump After 'IDO' Cancer Immunotherapy Combo Data Revealed

(TheStreet) May 17, 2017 - Attention cancer immunotherapy followers: The ASCO "IDO" party has kicked off. Never-before-seen data from mid-stage clinical trials combining Incyte's IDO inhibitor epacadostat with Keytruda and Opdivo, the anti-PD-1 checkpoint inhibitors marketed by Merck and Bristol-Myers Squibb, respectively, have been released tonight.

H. Jack West, MD (Posted: May 18, 2017)

quotesIn the feeding frenzy that is the business world's hype-driven interpretation of immunotherapy data, the point that the response rate in phase II trials is typically significantly higher than the better established phase III trial data is conveniently overlooked. Could IDO combinations represent a significant improvement? Sure. But docetaxel had a 25% response rate in progressing phase II trials, and carbo/taxol had a 50% response rate as first line treatment in early phase II work, and we all marvel at those crazy numbers when we learn the more sobering reality from far larger clinical trials and greater experience. This kind of breathless over-reaction to early studies is like a Darwin award of investment. Good luck, guys. Just remember that I told you not to jump off the cliff together, like a sea of lemmings. It's the same reflexive rather than conscious thought-driven process.quotes

Read Article arrow
Add Comment 1 Comment
forumImage

Amazon Is Hiring People to Break into the Multibillion-Dollar Pharmacy Market

(CNBC) May 16, 2017 - Amazon is hiring a business lead to figure out how the company can break into the multibillion-dollar pharmacy market.

Dean Gesme, MD (Posted: May 17, 2017)

quotesWatch closely as Amazon may seek to break traditional distribution models in the drug prescibing space!quotes

Read Article arrow
Add Comment 1 Comment
forumImage

Robert Comis, Piano Man, Clinical Trials Impresario, and ECOG-ACRIN Co-chair, Dies Unexpectedly at 71

(The Cancer Letter) May 12, 2017 - It’s possible that there were pianos that Bob Comis didn’t like. The luminary of clinical trials commandeered pianos wherever he found them—at hotel lounges and at the American Society of Clinical Oncology president’s receptions, where, year after year, he blasted his way through My Way.

Howard S. Hochster, MD (Posted: May 15, 2017)

quotesDr Bob Comis was a stolid and long-term leader of the old cooperative group system. He helped lead the transformation to the new NCTN. We will miss his guidance and wisdom. A real loss for our community.quotes

Read Article arrow
Add Comment 1 Comment

Meet the Editorial Board

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Associate Cancer Center Director, Yale Cancer Center P...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...